At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 771 enrolled
Drug / intervention
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Fixed Combination Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension and Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
In Brief
A Phase 3 clinical trial evaluating Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide 1% ophthalmic suspension, and 1 other intervention for Open-Angle Glaucoma and Ocular Hypertension. Completed, enrolled 771 participants.
Detailed Summary
The purpose of this study was to evaluate the safety and efficacy of Brinzolamide/Brimonidine in lowering intraocular pressure (IOP) relative to each of its individual active components in patients with open-angle glaucoma or ocular hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-Angle Glaucoma, Ocular Hypertension
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2011
Enrollment StartMay 2011
Primary CompletionJan 2013
TodayJul 2026
First PostedMar 9, 2011
Enrollment StartMay 1, 2011
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 15.3 years ago
Interventions
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspensiondrug
Brinzolamide 1% ophthalmic suspensiondrug
Brimonidine tartrate 0.2% ophthalmic solutiondrug